Salidroside reduces cerebral infarction and neurological deficits in MCAO; it reduces neuroinflammation and neural damage via activation of the PI3K/AKT/Nrf2/NF-κB pathway (81). The gene discussed is NFE2L2; the disease is brain infarction.